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Tuberculosis (TB) is an infectious disease caused by various strains of mycobacteria, usually 
Mycobacterium tuberculosis. Early diagnosis is important in TB disease control. The use of rapid diagnostic 
test (RDT) kits drastically reduces the time required for reaching clinical diagnosis and this has been successful 
in diagnosis of HIV, syphilis and more recently malaria to mention a few. What is the case for RDTs for 
diagnosis of tuberculosis? Thus, the aim of this study is to evaluate and compare the performances of results 
produced by different rapid diagnostic test strips available in the Nigerian market for TB. A total of ne 
hundred and eighty-four (184) subjects aged between 12-68 years were recruited for the study. These were 
referred from the chest clinic with a high index of suspicion of TB. Sputum samples were collected for AFB 
detection using the Ziehl-Neelsen and Auramine-phenol staining techniques. Blood samples were collected for 
serology tests using five (5) different rapid diagnostic test kits from different manufacturers, HIV status 
determination and evaluation of the haematological p rameters we carried out. As a result, there were 
significant differences in the results obtained between AFB tests and serological methods with P<0.01 in all 
cases. The sensitivity and specificity respectively of the five different kits were 28.6% and 32.0% (Nova), 
19.5% and 29.2% (Fistech), 9.1% and 27.1% (Diaspot), 12.4% and 27.7% (Abcon) and 12.4% and 27.7% 
(Global).finally, findings from this study show that these rapid serological tests are poor in diagnosing 
tuberculosis and cannot be recommended for use in this environment.  
© 2015 International Formulae Group. All rights reserved. 
 




Tuberculosis (TB) is a common and in 
many cases lethal, infectious disease caused 
by various strains of mycobacterium, usually 
Mycobacterium tuberculosis (Kumar et al., 
2007).  One third of the world’s population is 
thought to have been infected with M. 
tuberculosis and in 2013, there were an 
estimated 9 million new cases and 1.5 million 
associated deaths with 95% of the deaths 
occurring in low and middle income countries 
(WHO, 2014). More people in the developing 
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world are thought to contract tuberculosis 
because of compromised immunity (Lawn and 
Zumla, 2011), the high rates of HIV infection 
and the corresponding development of AIDS 
which is contributing to this burden and has 
led to a syndemic (Kwan and Ernst, 2011). 
At present, TB diagnosis in most 
developing countries relies largely on clinical 
features, x-ray, and microscopy of acid-fast 
sputum stains. Cultivation of the organism is 
the diagnostic gold standard in which the 
organism is cultured for weeks and there is 
also the possibility of susceptibility testing for 
the organisms which grow. This improves 
treatment efficiency, however, the turn-around 
time before a definite diagnosis can be 
obtained is 3-6 weeks, and facilities for 
culture are not readily available (Aderemi and 
Dada-Adegbola, 2013), even in tertiary health 
facilities. In high-incidence countries, TB 
control relies on passive case finding among 
individuals self-presenting to health care 
facilities, followed by either diagnosis based 
on clinical symptoms and/or laboratory 
diagnosis using sputum smear microscopy 
(Parsons et al., 2011). Serial sputum 
specimens are required (one taken on the spot 
and the second brought in the following 
morning), which means that the people are 
asked to make repeated visits to the health 
care center for specimen delivery and 
collection of results. For many patients, the 
costs of repeated visits to health care facilities 
are prohibitive, and patient dropout is a 
significant problem. In addition, the 
sensitivity of sputum smear microscopy has 
been reported to vary often depending on the 
diligence with which specimens are collected, 
smears are made, and stained smears are 
examined (Steingart et al., 2007). Also, TB 
smear microscopy is highly insensitive for 
HIV co-infected individuals and for children 
due to the reduced pulmonary bacillary loads 
in these patients (Getahun et al., 2007). In 
resource-poor countries, many smear 
microscopy laboratories are single-room and 
understaffed with poorly maintained 
microscopes, and some of these laboratories 
lack consistent sources of electricity and clean 
water. There are few opportunities for the 
training of staff and little staff capacity to 
handle high-volume workloads. Quality 
assurance programs including quality control 
and external quality assessments (EQAs) are 
often lacking. Thus, there is a critical need for 
new, sensitive, easy, and rapid point-of-care 
diagnostics and also for investments in 
laboratory infrastructure, quality assurance 
programs, and well-trained staff (Parsons et 
al., 2011). 
Timely diagnosis is crucial to TB 
control, as it provides early initiation of 
therapy and limits further disease spread. 
Several diagnostic methods for detecting TB 
have been used over the years including 
sputum smears and sputum culture. The 
tuberculin skin test (mantoux) for detection of 
latent TB is also in use. In addition, chest x-
rays are used to aid clinical diagnosis. All 
these methods have limitations. Newer tests, 
such as PCR-DNA amplification for TB 
diagnosis or interferon- gamma release assays 
for latent TB have been recently introduced. 
These tests are quite expensive and not 
practical for developing countries 
(Lyashchenko et al., 2000), due to their high 
cost and larger population with the disease 
burden. Rapid serological methods are an 
attractive alternative, since TB serodiagnosis 
is simple, inexpensive, relatively non–
invasive, and it does not depend on detection 
of mycobacteria (Lyashchenko et al., 2000).  
By using Serodiagnostic methods, the time 
required for reaching a clinical decision to 
treat a suspected case of tuberculosis can be 
drastically reduced, as in some cases the 
actual proof of an organism’s identity does not 
depend on its isolation or identification in a 
specific culture (Good and Mastro, 1989). 
Serodiagnosis is a rapid technique that is 
technically facile and if in routine use, is 
inexpensive. According to manufacturers of 
these rapid test kits for TB, the technique is 
also usable for diagnosing non pulmonary TB 
and is particularly attractive for the 
identification of TB manifestations in which 
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specimens are not easily accessible, example, 
skeletal TB. These rapid serological tests for 
TB are designed with antigens which are 
specific to Mycobacterium tuberculosis 
(Reddy et al., 2002). 
The TB Rapid Test Device (whole 
blood/serum/plasma) is a rapid test for 
qualitative detection of anti – TB antibodies 
(Isotypes IgG, IgM and IgA) in whole blood, 
serum or plasma specimens. The test utilizes a 
combination of recombinant antigens to detect 
elevated levels of anti – TB antibodies in 
whole blood, serum or plasma specimens. 
These rapid diagnostic test kits for 
tuberculosis made by various manufacturers 
are readily available in Nigeria. There are 
conflicting reports of the sensitivity and 
specificity of these RDTs in research carried 
out in India with a very wide range of l%-
98.5% reported and sensitivity ranging from 
53-99% (Reddy et al., 2002; Steingart et al., 
2012). Despite these reports, and the fact that 
no international guidelines recommend their 
use (Steingart et al., 2012), these RDTs are 
still very much in use especially in the private 
sector in many high burden countries 
including Nigeria (Greiner et al., 2012).  
Quality assurance and control of rapid 
immunochromatographic rapid diagnostic test 
strips are not usually carried out in Nigeria to 
ascertain the sensitivity and specificity of 
these test strips/cassettes. Indeed proper 
regulation of laboratory reagents and 
consumables is lacking. This has led to free 
importation of both standard, sub standard and 
out rightly fake products by marketers. This in 
turn could lead to wrong results which are 
detrimental to patient treatment and well 
being. In addition to the inherent limitations 
of the test kits themselves, some of these rapid 
test strips may give less than satisfactory 
results due to environmental constraints, poor 
storage conditions leading to either false 
positive, false negative or invalid results. The 
net effect is wrong diagnosis and 
mismanagement of the patient. 
This research was then designed to 
assess the validity, performance and 
reproducibility of some rapid 
immunochromatographic MTB-specific 
antibody detection tests using AFB positive 
patients who are not yet on anti-TB drugs. The 
study evaluated and compared the 
performances and results produced by five of 
the most popular rapid diagnostic test strips 
available in the Nigerian market by comparing 
results obtained with that in patients who were 
diagnosed by AFB and clinical assessment (in 
the absence of culture which is the gold 
standard). Due to the relationship between 
HIV and TB, HIV co-infected subjects were 
not excluded so long as they test positive for 
AFB. However, HIV positive individuals who 
tested negative for AFB were excluded 
because of the low sensitivity of AFB in HIV.  
 
MATERIALS AND METHODS 
Subjects 
A total number of 184 subjects (males 
and females) aged between 12 years to 68 
years were recruited from the tuberculosis 
directly observed treatment short course (TB 
DOTS) clinic, Nnamdi Azikiwe University 
Teaching hospital, Nnewi. These were 
suspected cases of tuberculosis referred from 
the chest clinic after clinical assessment of 
presenting symptoms and examination of 
chest x-rays.  
 
Exclusion/inclusion criteria  
TB positive patients who were already 
on anti-TB drugs were excluded from the 
study. Only freshly diagnosed treatment naïve 
TB patients were selected for the study.  
 
Ethical consideration  
The research design was approved by 
the Ethical committee of Nnamdi Azikiwe 
University Teaching Hospital Nnewi. 
Informed consent was obtained from each of 
the participants. Confidentiality was 
maintained. 
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Information such as age and history of 




Blood samples used were Ethylene 
diamine tetra-acetic acid (EDTA) 
anticoagulated blood (for estimation of the 
packed cell volume (PCV) and white blood 
cell count (WBC) and clotted blood (for 
serological detection of TB antibodies and 
HIV Screening) collected by venepuncture 
technique from the antecubital vein. Three 
sputum samples (for the Ziehl-Neelsen and 
Auramine-phenol techniques) were collected 
using a clean, sterile, wide-mouthed universal 
container. Both Ziehl-Neelsen and Auramine 
phenol techniques were used for each sample 
for AFB testing. 
 
Ziehl-Neelsen technique for M. tuberculosis 
The Ziehl-Neelsen technique is used to 
stain Mycobacterium species. Mycobacteria, 
unlike most others, do not stain well by the 
Gram technique. They can however be stained 
with carbol fuchsin combined with phenol. 
The stain binds to the mycolic acid in the 
mycobacterial cell wall. After staining, an 
acid decolourizing solution is applied. This 
removes the red dye from the background 
cells, tissue fibres, and any organisms in the 
smear except mycobacteria retain (hold fast 
to) the dye and therefore referred to as acid 
fast bacilli or simply AFB. Following 
decolourization, the smear is counterstained 
with methylene blue which stains the 
background material, providing a contrast 
colour against which the red AFB can be seen 
(Cheesbrough, 2002). Sputum smears were 
made on clean grease free slides and 
procedure was according to standard 
laboratory operating procedure. 
 
Auramine-Phenol technique 
Auramine fluoresces when illuminated 
(excited) by violet or ultra-violet (UV) light. It 
can be used to demonstrate AFB because it 
binds to the mycolic acid in the mycobacterial 
cell wall. No heating of the stain is required. 
After being stained with auramine, the smear 
is decolorized with acid alcohol which 
removes the dye from the background. The 
smear is then washed with a weak solution of 
potassium permanganate to darken the 
background. TB fluoresces white-yellow 
against a dark background (Cheesbrough, 
2002).  Sputum smears were made on clean 
grease free slides and procedure was 
according to standard laboratory operating 
procedure. 
For both AFB methods, the numbers of 
bacteria present were reported per high power 
field as follows: 
More than 10 AFB/field: +++ 
1-10 AFB/field: ++ 
10-1000 AFB/100 fields: + 
1-9 AFB/100 fields: exact number was 
reported. 
Although most AFB sputum smear 
positive patients are indeed infected with M.
tuberculosis (Idigbe et al., 1986), samples can 
be contaminated with environmental 
mycobacteria and this is often seen in stored 
samples (Salvakumar et al., 2006). To 
overcome this, all samples were examined by 
experienced microscopists with 24 hours of 
smear preparation. Freshly prepared stains 




Two different methods were used 
namely: Inverness DetermineTM 1 & 2 
(Inverness Medical Japan Co. Ltd, Japan) and 
STAT-PAK (Chembio Diagnostic system, 
New York, USA). HIV seropositive results 
using these two methods are used to classify 
participants as HIV infected. Tests were 
carried out according to manufacturer’s 
instructions. 
Appearance of two distinct colored 
lines, one at the control region and the other at 
the test region indicates a positive result while 
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appearance of one colored line at the control 
region indicates a negative result.  
 
TB antibodies serological testing 
  Five different rapid test kits were 
purchased from suppliers who import and 
distribute these products in the country. They 
are all based on the same principle of 
detection of antibodies to tuberculosis. The 
TB Tuberculosis Rapid Test Device (Whole 
blood/serum/plasma) is a qualitative, solid 
phase, two site sandwich immunoassay for the 
detection of anti-TB antibodies in whole 
blood, serum or plasma specimens. The 
membrane is pre-coated with TB recombinant 
antigen on the test line region of the device. 
During testing the anti-TB antibodies, if 
present in whole blood, serum or plasma 
specimen react with the particles coated with 
TB recombinant antigen. The mixture 
migrates upward on the membrane 
chromatographically by capillary action to 
react with TB recombinant antigen on the 
membrane and generate a colored line. The 
presence of this colored line in the test region 
indicates a positive result, while its absence 
indicates a negative result. To serve as a 
procedural control, a colored line will always 
appear in the control line region indicating 
that proper volume of specimen has been 
added and membrane wicking has occurred 
(Bothamley, 1995). Appearance of two 
distinct colored lines, one at the control region 
and the other at the test region indicates a 
positive result while appearance of one 
colored line at the control region indicates a 
negative result. The intensity of the color at 
the test region varies depending on the 
concentration of anti-TB antibodies present in 
the specimen. All test procedures were carried 
out according to the different manufacturers’ 
instructions. Serum samples were used for all 
analyses.  
The packed cell volume and total white 
blood cell counts were done by manual 
methods as described by Bain et al., 2008, 
using standard operating procedures. 
Statistical analysis 
Data were analyzed using Graph pad 
Prism version 5.03. Spearman’s correlations, 
Pearson’s Chi-Square were used.  Sensitivity 
and specificity for the diagnostic method were 
performed. Positive (PPV) and negative 
(NPV) predictive values as well as likelihood 
ratios were calculated. The level of 
significance was set at P<0.05.  
 
RESULTS 
A total of 184 subjects referred from 
the chest clinic participated in the study. Of 
these 120 were TB positive subjects who were 
positive for TB via the sputum smear 
microscopy. The mean PCV (L/L) were 38.11 
+ 3.37 and 40.22 + 6.78 in the AFB positive 
subjects and negative subjects respectively. 
The mean WBC counts (109/l) were 6.17 + 
2.38 and 5.67 + 0.85 in the AFB positive 
subjects and negative subjects respectively 
(Table 1). Serum samples from each AFB 
positive and negative subject was subjected to 
further testing using all five RDTs and the 
results are shown in table 2. The mean 
sensitivity and 95% confidence interval (C.I) 
are 12.4% (C.I=7.3-19.1) for Abcon, 9.1% 
(C.I=4.7-15.3) for Diaspot, 19.5% (C.I= 13.4-
26.7) for Fistech, 12.4% (C.I=7.3-19.1) for 
Global and 28.6% (C.I=21.8-36.0) for Nova. 
The specificity and 95% confidence interval 
are 27.7% (C.I=22.0-33.9) for Abcon, 27.1% 
(C.I=21.6-33.3) for Diaspot, 29.2% (C.I= 
23.3-35.7) for Fistech, 27.7% (C.I=22.0-33.9) 
for Global and 32% (C.I=25.6-38.9) for Nova.  
The negative predictive values, positive 
predictive values and likelihood ratios are 
shown in table 2.  
There were no significant differences in 
the PCV (P=0.451) and WBC (P=0.561) 
values among the subjects who are false 
negative with the RDTs and those who are 
true positives. Thus, these do not have any 
effect on the test results produced by these 
kits. 
Of the 120 TB positive test subjects, 
forty-five (45) of them were HIV positive 
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(37.5%) while seventy-five (75) of the 
subjects (62.5%) were HIV negative (Figure 
1). None of the TB negative subjects included 
in the study was positive for HIV.  
Among the HIV positive individuals 
who were AFB positive, 31.3% tested positive 
in one or more test kits while among the AFB 
positive subjects who were not co-infected 
with HIV, 46.1% tested positive in one or 
more test kits. The sensitivity relationship of 
the RDTs with HIV positive status 
(immunocompromised) calculated is 6.3% for 
Nova, 13% for Fistech, 6.3% for Diaspot, 
13% for Abcon and 19% for Global while the 
sensitivity relationship with HIV negative 
status gave 44% for Nova, 24% for 
Fistech,12% Diaspot,16% for Abcon and 8% 
for Global. Thus, HIV infection affects the 
performance of the test kits. In addition, there 
was a weak positive correlation in the 
performance of the test kits when comparing 
mycobacterial load (as shown by the number 
of mycobacteria observed microscopically) 
and HIV infection (r=0.373), thus, with higher 
mycobacterial load, detection in the HIV co-
infected increases weakly. On the other hand, 
in the HIV negative, there was no clear 
relationship (in the 5 different makes of the 
RDTs) between the mycobacterial density and 
the performance of the test kits. 
Age and sex did not appear to have any 
effect on performance of the test kits.
 
 
Table 1: Sputum smears, age, sex, packed cell volume (PCV) and Total white blood cell (TWBCT) 











AFB positive  
(n=120)                                   
36.5 + 13.5 Male:     69(57.5%) 
Female: 51(42.5%) 
38.1 +3.4 6. 2+.38  
AFB negative  
(n=64) 
39.2 +15.6 Male:     31(48.4) 
Female: 33(51.6) 
40.2+0.78 5.7+0.85  
Total (184)      
 
Table 2:  Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) 
and likelihood ratios of the serology tests of rapid TB test kits. Confidence intervals (C.I) are also 
shown.   
 



















































(Not in %) Likelihood 
ratio 0.17 0.12 0.28 0.17 0.42 
 
  









Though newer methods of TB detection 
such as nucleic acid amplification-based 
diagnostic systems are highly accurate and 
precise and can provide a definite diagnosis 
within hours, high cost is a barrier for 
resource poor countries to scale up (Boehme 
et al., 2010). Most patients have access to only 
smear microscopy and even this is under 
utilized in the private sector (Jaroslawski and 
Pai, 2012). Rapid serological tests have been 
used successfully in the diagnosis of many 
infectious diseases including HIV and viral 
hepatitis and have been available for decades. 
The ease of performing these tests as well as 
time it takes to reach a diagnosis certainly 
makes these rapid diagnostic tests very 
attractive. Rapid serologic tests for detection 
of active TB have been commercially 
available for decades (Steingart, 2012) and 
though no international guidelines recommend 
their use, dozens of these commercial test kits 
are offered for sale in many parts of the world 
(Jaroslawski and Pai, 2012) and there is a 
thriving market for them. These serological 
tests are widely used in high-burden countries 
including Nigeria (Greiner et al., 2012).  An 
estimated 1.5 million serological TB tests are 
performed in India alone every year mostly in 
the private sector (Greiner et al., 2012). The 
exact estimate for Nigeria is unknown. With 
reports that these serological tests are 
inaccurate yet widely used (Steingart, 2012; 
Greiner et al., 2012; Jaroslawski and Pai, 
2012) the validity of the test kits available for 
use in Nigeria were assessed.   
Findings from this study show that the 
sensitivity and specificity of these kits are 
very low with Nova that gave the best result 
giving a sensitivity of 28.6% and specificity 
of 32%. The result of our study does not agree 
with the findings of Reddy et al., 2012 carried 
out in India.  They reported specificity of 
99.42% with sensitivity of 98.52% (n=241) 
and in cases of multiple infections, the 
specificity was 93.15% with a lower 
sensitivity of 73.52% (n = 141).  This does not 
conform to the findings of this study though 
the authors used a particular kit developed by 
them. However, the findings from this study 
are in accordance with reports by Steingart et 
al., 2012 from India which reviewed different 
TB serology kits. Their study on the 
performance of rapid diagnostic tests for 
pulmonary tuberculosis gave sensitivity 
results ranging from 1% to 59.71% and 
specificity ranging from 57.05% to 98.66%. 
The two studies also identified that evaluated 
HIV-infected TB patients test sensitivities 
were poor most likely due to their immune 
state and the poor production of antibodies 
which are to be detected via this method. The 
sensitivity and specificity with all five 
serology test kits used in this study are low 
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and one may argue that these were not 
purchased directly from the manufacturers, 
and as such poor storage may be an issue. 
That maybe true but only to an extent because 
that is the reality we face. Hardly any end user 
purchases these and other such test kits 
including the highly successful ones directly 
from the manufacturers, so these test results 
are a representation of diagnostic test results 
especially from the private sector where these 
rapid tests are mostly in use.  
It was expected that the higher the 
mycobacterial density (number of +s) 
produced from the AFB smear microscopy 
method in HIV negative subjects the higher 
the production of true positives from the kits. 
This was not the case either in the HIV-
negative or HIV positive group. Neither age 
nor sex appears to affect the performance of 
these kits.  
The basic premise of serological tests is 
ease, rapidity and ever increasing demand in 
endemic countries. Hence, these rapid test kits 
have always been the first choice for small 
time laboratories that may be operating in 
rural areas without electricity and qualified 
man power. The use of these RDTs in the 
accurate diagnosis of HIV has been a major 
boost for these kits in recent years,  however, 
unlike the RDTs for HIV and malaria 
detection, there has been no clear 
encouragement to use these RDTs for 
diagnosis of TB, yet the market for these kits 
are thriving. It has been reported that in some 
places, these kits are utilized without 
bothering much on quality of tests and 
implications of false-positive and false- 
negative results (Singh and Katoch., 2011). 
These kits are not reliable for the diagnosis of 
TB in this environment with the highest 
sensitivity value of 28.6% from the Nova test 
kit brand which is very low in terms of 
sensitivity and specificity for diagnosis. The 
data from this study, as well as data from 
other studies and WHO evaluation (WHO, 
2006) unambiguously show that TB serology 
should not be used for TB diagnosis. The idea 
that serology is cheaper has no basis, as 
thorough serology profile (IgG, IgA, IgM) 
costs more than even liquid culture and PCR 
test combined (Singh and Katoch.,2011). 
There is no evidence that existing commercial 
serological assays improve patient-important 
outcomes, and high proportions of false-
positive and false-negative results adversely 
impact patient safety (Steingart et al., 2012).  
Misdiagnosis of TB is harmful both to 
individual patients and to public health; every 
missed TB diagnosis may result in additional 
TB transmission (Greiner et al., 2012). It is 
therefore, recommended that these tests 
should not be used in individuals suspected of 
active pulmonary or extrapulmonary TB, 
irrespective of their HIV status (Steingart et 
al., 2011). Findings from this study lead us to 
agree with these statements. The search for 
appropriate serological diagnostic test kits for 
tuberculosis will continue, and till such a time 
that it is inferred from appropriate quality 
control tests that such is available, use of these 
available test kits can hardly be 
recommended. With these finding, it is 
recommended that local policy advising 
against the use of these serological test for TB 
should be made. 
 
Conclusion 
Currently available commercial 
serological tests for TB are not reliable. The 
present situation where laboratory 
consumables are not regulated and quality 
control to assess accuracy and precision are 
not in place can only do more harm than good. 
Appropriate legislation should be put in place 
urgently to address these lapses. More funding 
is advocated in order to provide the relatively 
new molecular diagnostic equipment such as 
the PCR GeneXpert and Interferon release 
assays which are accurate and fast in order to 
tackle the high tuberculosis disease burden.  
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